During breast cancer progression from estrogen-dependent to a more invasive tumor, ERα expression is decreasing until an estrogen-independent phenotype occurs, which correlates with a more aggressive phenotype and poor clinical outcome. This evidence concerns the gene ESR1 and breast cancer.